CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Title
CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
Authors
Keywords
esophageal cancer; Cdk4 protein; CDK6 protein; abemaciclib; preclinical drug evaluations
Journal
Oncotarget
Volume 8, Issue 59, Pages -
Publisher
Impact Journals, LLC
Online
2017-11-02
DOI
10.18632/oncotarget.22244

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More